Shionogi & Co., Ltd. recently presented findings at IDWeek 2024 from the PROVE study, the largest global real-world evidence study on cefiderocol (marketed as Fetroja®/Fetcroja®), a siderophore cephalosporin antibiotic for treating seriously ill adult patients with Gram-negative (GN) bacterial infections.…
BeiGene Showcases Promising Waldenström’s Macroglobulinemia Research at IWWM 2024 San Mateo, Calif. – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology leader, announced its participation in the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM) held in Prague…
AstraZeneca Showcases Key Advances in Respiratory Infection Protection at IDWeek 2024 AstraZeneca is set to present significant new findings on the protection against serious respiratory infections caused by respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and COVID-19 at IDWeek 2024,…
Etcembly and University of Surrey Launch Study to Transform Cancer Treatment British techbio innovator Etcembly is collaborating with researchers from the University of Surrey to launch a groundbreaking study aimed at revolutionizing cancer treatment. The research will analyze the immune…
STRIDE-8 Study Results Highlight CAPVAXIVE’s Efficacy in Pneumococcal Disease Prevention CAPVAXIVE Demonstrates Strong Immune Response and Coverage Against Major Serotypes RAHWAY, N.J. — Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, presented promising results from the…
ViiV Healthcare Presents Real-World Evidence for Apretude (Cabotegravir Long-Acting) at IDWeek 2024 GSK plc (LSE/NYSE: GSK) has announced that ViiV Healthcare, a global leader in HIV treatment and prevention, has shared new real-world evidence on the effectiveness, adherence, and quality-of-life…
Bayer to Present Latest Research on Menopausal Sleep Disturbances at IMS 2024 Bayer is set to showcase its latest research on menopause symptoms, particularly sleep disturbances, at the 19th World Congress of the International Menopause Society (IMS) from October 19-22,…
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024 GenSight Biologics (Euronext: SIGHT), a biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has announced new scientific data on its gene therapy, LUMEVOQ®,…
Colossal, a company focused on de-extinction and species preservation, has made significant strides in its efforts to bring back the thylacine, an iconic Australian marsupial that has been extinct since 1936. The company announced breakthroughs across all stages of the…
Grifols Achieves Record Score in 2024 S&P Global Corporate Sustainability Assessment Grifols Secures 70 Points, Demonstrating a Seven-Point Improvement Over Previous Year Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global healthcare company and manufacturer of plasma-derived medicines, has…
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced promising top-line results from a Phase 3 clinical trial assessing the effectiveness of Zepzelca® (lurbinectedin) combined with the PD-L1 inhibitor atezolizumab (Tecentriq®). This combination therapy was evaluated as a maintenance treatment for adults…
Novotech, a full-service international clinical contract research organization (CRO), is proud to announce its recognition as a U.S. Great Place to Work® certified company. This prestigious certification underscores Novotech’s commitment to fostering a flexible, inclusive, and innovative work environment, where…